Novo Nordisk A/S (NVO) Description, Stock price, News & Info.

#ThinkSabio Latest News

NOVO NORDISK - TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING A STATISTICALLY SIGNIFICANT AND SUPERIOR WEIGHT LOSS AT WEEK 72 WITH SEMAGLUTIDE 7.2 MG VERSUS PLACEBO.

Leave a Reply

Your email address will not be published. Required fields are marked *